# SAFEstart Feeding Intolerance Study Phase II

> **NCT00331201** · PHASE2 · COMPLETED · sponsor: **Intermountain Health Care, Inc.** · enrollment: 20 (—)

## Conditions studied

- Feeding Intolerance
- Abdominal Distention
- Gastric Residual
- Emesis and Diarrhea
- Blood in Stool

## Interventions

- **DRUG:** SAFEstart

## Key facts

- **NCT ID:** NCT00331201
- **Lead sponsor:** Intermountain Health Care, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-07
- **Primary completion:** —
- **Final completion:** 2006-04
- **Target enrollment:** 20 (—)
- **Last updated:** 2006-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00331201

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00331201, "SAFEstart Feeding Intolerance Study Phase II". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00331201. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*